SCHEMBL17508043

SCHEMBL17508043

CCOC(=O)c1cccc(Sc2c(Cl)n(-c3cccnc3)c3c(F)c(Cl)ccc23)c1F

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 11/20 0.59
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ALDH1A1 P00352 2/20 0.35
TP53 P04637 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16739486 0.92 ENPP2 (0.51) ENPP2NPC1RAB9AALDH1A1TP53
SCHEMBL16751070 0.89 ENPP2 (0.63) ENPP2NPC1RAB9AALDH1A1TP53
SCHEMBL30146966 0.87 ENPP2 (0.67) ENPP2
SCHEMBL16739496 0.87 ENPP2 (0.67) ENPP2
SCHEMBL30146964 0.86 ENPP2 (0.66) ENPP2
SCHEMBL17508049 0.86 ENPP2 (0.66) ENPP2
SCHEMBL17508046 0.86 ENPP2 (0.66) ENPP2
SCHEMBL16739516 0.86 ENPP2 (0.69) ENPP2ALDH1A1HTTMAPTHPGD
SCHEMBL17508047 0.85 ENPP2 (0.56) ENPP2
SCHEMBL29657216 0.85 ENPP2 (0.56) ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 US disclosed
CN-110372671-B Autotaxin inhibitor compounds 赛博治疗有限责任公司 2023-02-21 CN disclosed
US-20220265608-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2022-08-25 US disclosed
US-11344533-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2022-05-31 US disclosed
US-11344533-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2022-05-31 US disclosed
EP-3878848-A1 AUTOTAXIN INHIBITING INDOLE COMPOUNDS Sabre Therapeutics LLC (US) 2021-09-15 EP disclosed
EP-3071561-B1 AUTOTAXIN INHIBITOR COMPOUNDS SABRE THERAPEUTICS LLC (US) 2021-03-24 EP disclosed
EP-3071561-B1 AUTOTAXIN INHIBITOR COMPOUNDS SABRE THERAPEUTICS LLC (US) 2021-03-24 EP disclosed
US-9468628-B2 Autotaxin inhibitor compounds PHARMAKEA, INC (US) 2016-10-18 US disclosed
US-20160235713-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-08-18 US disclosed
US-20160235713-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-08-18 US disclosed
US-20160235713-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-08-18 US disclosed
US-9334261-B2 Autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2016-05-10 US disclosed
US-9334261-B2 Autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2016-05-10 US disclosed
US-9334261-B2 Autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2016-05-10 US disclosed
US-20160046614-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-02-18 US disclosed
US-20160046614-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-02-18 US disclosed
US-20160046614-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11779568-B2 Autotaxin inhibitor compounds ENPP2, SERPINB1, SERPINE1 ENPP2 1/4885NPC1 2262/4885RAB9A 2156/4885
US-20160046614-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 ENPP2 1/4885NPC1 2262/4885RAB9A 2156/4885
US-11344533-B2 Autotaxin inhibitor compounds ENPP2, SERPINB1, SERPINE1 ENPP2 1/4885NPC1 2262/4885RAB9A 2156/4885
US-20220265608-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 ENPP2 1/4885NPC1 2262/4885RAB9A 2156/4885
US-20160235713-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 ENPP2 1/4885NPC1 2262/4885RAB9A 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.